Systematic review and meta-analysis of the effect of metformin treatment on overall mortality rates in women with endometrial cancer and type 2 diabetes mellitus

Maturitas

Volumn 101, Issue , 2017, Pages 6-11

  Perez Lopez, Faustino R ^a   Pasupuleti, Vinay ^b   Gianuzzi, Ximena ^c   Palma Ardiles, Gabriela ^c   Hernandez Fernandez, Wendy ^c   Hernandez, Adrian V ^c,d  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b ProEd Communications Inc   (United States)

^c UNIVERSIDAD PERUANA DE CIENCIAS APLICADAS   (Peru)

^d HARTFORD HOSPITAL   (United States)

Author keywords

Endometrial cancer; Metformin; Overall mortality; Type 2 diabetes mellitus

Indexed keywords

INSULIN; METFORMIN; ANTIDIABETIC AGENT;

BODY MASS; CANCER MORTALITY; CLINICAL OUTCOME; DISEASE COURSE; DRUG EFFECT; ENDOMETRIUM CANCER; FEMALE; HUMAN; INSULIN RESISTANCE; META ANALYSIS; METASTASIS; MORTALITY RATE; NEWCASTLE-OTTAWA SCALE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SYSTEMATIC REVIEW; DIABETES MELLITUS, TYPE 2; ENDOMETRIAL NEOPLASMS; MORTALITY; RETROSPECTIVE STUDY;

DIABETES MELLITUS, TYPE 2; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; RETROSPECTIVE STUDIES;

EID: 85017648897     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2017.04.001     Document Type: Review

References (45)

1. [1] Felix, A.S., Yang, H.P., Bell, D.W., Sherman, M.E., Epidemiology of endometrial carcinoma: etiologic importance of hormonal and metabolic influences. Adv. Exp. Med. Biol. 943 (2017), 3–46.
2. [2] Friberg, E., Orsini, N., Mantzoros, C.S., Wolk, A., Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50 (2007), 1365–1374.
3. [3] Brinton, L.A., Trabert, B., Anderson, G.L., Falk, R.T., Felix, A.S., Fuhrman, B.J., et al. Serum estrogens and estrogen metabolites and endometrial cancer risk among postmenopausal women. Cancer Epidemiol. Biomark. Prev. 25 (2016), 1081–1089.
4. [4] Hernandez, A.V., Pasupuleti, V., Benites-Zapata, V.A., Thota, P., Deshpande, A., Perez-Lopez, F.R., Insulin resistance and endometrial cancer risk: a systematic review and meta-analysis. Eur. J. Cancer 51 (2015), 2747–2758.
5. [5] Renehan, A.G., Tyson, M., Egger, M., Heller, R.F., Zwahlen, M., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371 (2008), 569–578.
6. [6] Fader, A.N., Arriba, L.N., Frasure, H.E., von Gruenigen, V.E., Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol. Oncol. 114 (2009), 121–127.
7. [7] Campbell, P.T., Newton, C.C., Patel, A.V., Jacobs, E.J., Gapstur, S.M., Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 35 (2012), 1835–1844.
8. [8] Thakkar, B., Aronis, K.N., Vamvini, M.T., Shields, K., Mantzoros, C.S., Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism 62 (2013), 922–934.
9. [9] Tsilidis, K.K., Kasimis, J.C., Lopez, D.S., Ntzani, E.E., Ioannidis, J.P., Type 2 diabetes and cancer: umbrella review of metaanalyses of observational studies. BMJ, 350, 2015, g7607.
10. [10] Arnold, M., Jiang, L., Stefanick, M.L., Johnson, K.C., Lane, D.S., LeBlanc, E.S., et al. Duration of adulthood overweight, obesity, and cancer risk in the Women's Health Initiative: a longitudinal study from the United States. PLoS Med, 13, 2016, e1002081.
11. [11] Aarestrup, J., Gamborg, M., Tilling, K., Ulrich, L.G., Sørensen, T.I., Baker, J.L., Childhood body mass index growth trajectories and endometrial cancer risk. Int. J. Cancer 140 (2017), 310–315.
12. [12] Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G.F., Pellegrini, F., Nicolucci, A., Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS ONE, 8, 2013, e71583.
13. [13] Zhang, P., Li, H., Tan, X., Chen, L., Wang, S., Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 37 (2013), 207–218.
14. [14] Mitsuhashi, A., Kiyokawa, T., Sato, Y., Shozu, M., Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer 120 (2014), 2986–2995.
15. [15] Sivalingam, V.N., Kitson, S., McVey, R., Roberts, C., Pemberton, P., Gilmour, K., et al. Measuring the biological effect of presurgical metformin treatment in endometrial cancer. Br. J. Cancer 114 (2016), 281–289.
16. [16] Perez-Lopez, F.R., Metformin treatment and evolution of endometrial cancer. Climacteric 17 (2014), 207–209.
17. [17] Zhang, Z.J., Li, S., The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes. Metab. 16 (2014), 707–710.
18. [18] Wells, G.A., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2016 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (21 December 2016).
19. [19] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA Group, Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. J. Clin. Epidemiol. 62 (2009), 1006–1012.
20. [20] DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control. Clin. Trials 7 (1986), 177–188.
21. [21] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
22. [22] Higgins, J.P., Commentary: heterogeneity in meta-analysis should be expected and appropriately quantified. Int. J. Epidemiol. 37 (2008), 1158–1160.
23. [23] Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple graphical test. BMJ 315 (1997), 629–634.
24. [24] Review Manager (RevMan) [Computer program]. Version 5.1. 2011, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen.
25. [25] Ko, E.M., Walter, P., Jackson, A., Clark, L., Franasiak, J., Bolac, C., et al. Metformin is associated with improved survival in endometrial cancer. Gynecol. Oncol. 132 (2014), 438–442.
26. [26] Nevadunsky, N.S., Van Arsdale, A., Strickler, H.D., Moadel, A., Kaur, G., Frimer, M., et al. Metformin use and endometrial cancer survival. Gynecol. Oncol. 132 (2014), 236–240.
27. [27] Lemanska, A., Zaborowski, M., Spaczynski, E., Nowak-Markwitz, E., Do endometrial cancer patients benefit from metformin intake?. Ginekol. Pol. 86 (2015), 419–423.
28. [28] Al Hilli, M.M., Bakkum-Gamez, J.N., Mariani, A., Cliby, W.A., Mc Gree, M.E., Weaver, A.L., et al. The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts. Gynecol. Oncol. 140 (2016), 270–276.
29. [29] Ezewuiro, O., Grushko, T.A., Kocherginsky, M., Habis, M., Hurteau, J.A., Mills, K.A., et al. Association of metformin use with outcomes in advanced endometrial cancer treated with chemotherapy. PLoS ONE, 11, 2016, e0147145.
30. [30] Seebacher, V., Bergmeister, B., Grimm, C., Koelbl, H., Reinthaller, A., Polterauer, S., The prognostic role of metformin in patients with endometrial cancer: a retrospective study. Eur. J. Obstet. Gynecol. Reprod. Biol. 203 (2016), 291–296.
31. [31] Mei, Z.B., Zhang, Z.J., Liu, C.Y., Liu, Y., Cui, A., Liang, Z.L., Wang, G.H., Cui, L., Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. PLoS ONE, 9, 2014, e91818.
32. [32] Arrieta, O., Varela-Santoyo, E., Soto-Perez-de-Celis, E., Sánchez-Reyes, R., De la Torre-Vallejo, M., Muñiz-Hernández, S., et al. Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer. BMC Cancer, 16, 2016, 633.
33. [33] Ruiter, R., Visser, L.E., van Herk-Sukel, M.P., Coebergh, J.W., Haak, H.R., Geelhoed-Duijvestijn, P.H., et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 35 (2012), 119–124.
34. [34] Soranna, D., Scotti, L., Zambon, A., Bosetti, C., Grassi, G., Catapano, A., et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 17 (2012), 813–822.
35. [35] Häggström, C., Van Hemelrijck, M., Zethelius, B., Robinson, D., Grundmark, B., Holmberg, L., et al. Prospective study of type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer. Int. J. Cancer 140 (2017), 611–617.
36. [36] Tsilidis, K.K., Capothanassi, D., Allen, N.E., Rizos, E.C., Lopez, D.S., van Veldhoven, K., et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care 37 (2014), 2522–2532.
37. [37] Kowall, B., Stang, A., Rathmann, W., Kostev, K., No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. Pharmacoepidemiol. Drug Saf. 24 (2015), 865–874.
38. [38] Bo, S., Ciccone, G., Rosato, R., Villois, P., Appendino, G., Ghigo, E., et al. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes Obes. Metab. 14 (2012), 23–29.
39. [39] Nead, K.T., Sharp, S.J., Thompson, D.J., Painter, J.N., Savage, D.B., Semple, R.K., et al. Evidence of a causal association between insulinemia and endometrial cancer: a Mendelian randomization analysis. J. Natl. Cancer Inst., 107, 2015 pii: djv178.
40. [40] de Barros Machado, A., Dos Reis, V., Weber, S., Jauckus, J., Brum, I.S., von Eye Corleta, H., et al. Proliferation and metastatic potential of endometrial cancer cells in response to metformin treatment in a high versus normal glucose environment. Oncol. Lett. 12 (2016), 3626–3632.
41. [41] Xie, Y., Wang, J.L., Ji, M., Yuan, Z.F., Peng, Z., Zhang, Y., et al. Regulation of insulin-like growth factor signaling by metformin in endometrial cancer cells. Oncol. Lett. 8 (2014), 1993–1999.
42. [42] Zhong, T., Men, Y., Lu, L., Geng, T., Zhou, J., Mitsuhashi, A., et al. Metformin alters DNA methylation genome-wide via the H19/SAHH axis. Oncogene, 2016, 10.1038/onc.2016.391.
43. [43] SGO Clinical Practice Endometrial Cancer Working Group, Burke, W.M., Orr, J., Leitao, M., Salom, E., Gehrig, P., Olawaiye, A.B., et al. Endometrial cancer: a review and current management strategies. Gynecol. Oncol. 134 (2014), 385–392.
44. [44] The ESMO–ESGO–ESTRO Endometrial Consensus Conference Working Group, Colombo, N., Creutzberg, C., Amant, F., Bosse, T., González-Martín, A., Ledermann, J., et al. ESMO–ESGO–ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Radiother. Oncol. 117 (2015), 559–581.
45. [45] Fotopoulou, C., Kraetschell, R., Dowdy, S., Fujiwara, K., Yaegashi, N., Larusso, D., et al. Surgical and systemic management of endometrial cancer: an international survey. Arch. Gynecol. Obstet. 291 (2015), 897–905.